Investigation questions motives behind post-marketing studies

June 12, 2012, British Medical Journal

An investigation published by the BMJ today raises concern about the motives behind post-marketing studies of new treatments for diabetes and calls for better regulation to ensure "a proper balance" between the commercial and clinical functions of these studies.

Experts warn that these studies are fuelling "catastrophic health expenditure" in , and a former drug industry employee admits that many of these studies "had more marketing than science behind them."

In theory, post-marketing studies are primarily used to show that a new drug is safe and effective in the real world. But there are concerns that many of these studies are predominantly serving a marketing purpose – to promote new, more expensive treatments and influence the prescribing habits of physicians.

Concerned about the role and legitimacy of post-marketing studies for new insulins, Edwin Gale, Emeritus Professor of Diabetic Medicine at the University of Bristol, analysed their use by three main insulin manufacturers (Eli Lilly, Novo Nordisk and Sanofi-Aventis).

New analogue insulins can cost up to four times as much as conventional human insulin, but evidence shows that they offer little benefit to most people with type 2 .

Yet Professor Gale found that nearly 400,000 people worldwide have been recruited into post-marketing studies of insulin analogues since 2005. One company recruited nearly 360,000 individuals. Most studies were carried out in middle or low income countries, had limited scientific value, and promoted wider use of more expensive insulins. Most patients are also likely to remain on the new insulins at the end of the studies.

It seems reasonable to ask whether a company would invest in such large scale activities without a good commercial rationale, writes Gale. Although physicians may participate in good faith, he says that "the patient or healthcare system pays for a more expensive agent instead of one that is cheaper and equally effective, and the public is offered misleading claims of comparative merit based on studies of limited scientific value."

In an accompanying article, John Yudkin, Emeritus Professor of Medicine at University College London argues that post-marketing studies "may be driving households into catastrophic health expenditure."

He points to Novo Nordisk's PREDICTIVE study, which paid doctors in 26 countries to start 47,565 people with diabetes on the company's insulin analogue, Levemir. Professor Yudkin calculates that in India, where 3,435 patients were enrolled in the study, and where patients must cover drug costs themselves, the annual cost of Levemir would be eight times more than a generic human insulin.

Novo Nordisk can be justifiably proud of some of their social responsibility initiatives over the past 10 years, he says, "but it now needs to reclaim the moral high ground."

In a third article, a former drug industry employee reveals that some post-marketing studies "had more marketing than science behind them" and admits to "playing" with the data "to ensure that the benefits of the drug were emphasised and the disadvantages were minimised where possible."

Wishing to remain anonymous, the author describes other questionable practices, including the use of key opinion leaders to add credibility to the results and to influence decision makers and other prescribers.

"Allowing companies to focus more time and efforts on drug development, or increasing transparency by encouraging industry authors to disclose the fact that the research has commercial objectives (as long as these are balanced with scientific value) would definitely help to develop better drugs for patients," they conclude.

Explore further: Experimental diabetes drugs offer patients hope

Related Stories

Experimental diabetes drugs offer patients hope

June 11, 2012
Some experimental diabetes treatments in late testing offer patients hope of better controlling their blood sugar and weight and preventing dangerously low blood sugar, all big challenges for millions of diabetics.

Researchers challenge post-marketing trial practices

May 3, 2012
Current research ethics focuses on protecting study participants, but according to bioethicists from Carnegie Mellon University and McGill University, these efforts fail to prevent problems that undermine the social value ...

Clinical study of epilepsy drug may have been purely promotional

June 27, 2011
Yale School of Medicine researchers have found that a clinical trial of the epilepsy drug gabapentin may have been a "seeding trial" used by a pharmaceutical company to promote the drug and increase prescriptions, according ...

Recommended for you

Health insurance plans may be fueling opioid epidemic

June 22, 2018
Health care insurers including Medicare, Medicaid and major private insurers have not done enough to combat the opioid epidemic, suggests a study led by researchers at Johns Hopkins Bloomberg School of Public Health.

Overdose risk quintuples with opioid and benzodiazepine use

June 22, 2018
In the first 90 days of concurrent opioid and benzodiazepine use, the risk of opioid-related overdose increases five-fold compared to opioid-only use among Medicare recipients, according to a new study from the University ...

Discovery opens door for synthetic opioids with less addictive qualities

June 1, 2018
Making opioids from sugar instead of from field grown opium poppies has the potential to solve many of the problems associated with manufacturing strong pain killers.

US doctors prescribing fewer opioid painkillers: report

May 31, 2018
US doctors reduced the number of prescriptions for opioid painkillers last year, continuing a five-year trend, in an effort to reverse a deadly drug abuse epidemic, a report released Thursday said.

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.